Novel Anti-Cancer Therapeutics and Therapies
Investigational New Drugs
December 19, 2018
Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers
Adenosine suppresses antitumor immune responses via A2a and A2b receptors expressed on intratumoral immune cells. This effect is mediated by increased cyclic adenosine 5′-monophosphate (AMP) levels and phosphorylation of cyclic AMP response element binding protein (CREB). We conducted a phase 1, placebo-controlled, single-ascending-dose (SAD) and multiple-ascending-dose (MAD) study to assess the safety, tolerability, pharmacokinetics (PK), including food effect (FE), and pharmacodynamics (PD) of oral AB928, a novel dual A2aR/A2bR antagonist, in healthy volunteers.
The news source of record covering the development of innovative human therapies
Actionable Intelligence • Incisive Analysis
June 20, 2018 – Volume 29, No. 119
Adenosine dreams fueling new approaches in cancer; Arcus embarks on phase I
By Randy Osborne, Staff Writer
Although Merck & Co. Inc. continues to chalk up investor-pleasing sales with Keytruda (pembrolizumab) and Bristol-Myers Squibb Co. (BMS) keeps doing well with Opdivo (nivolumab), researchers have yet to strike upon the best combinations with other agents.
The prospect of using an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor took a hit in April when Incyte Corp. and Kenilworth, N.J.-based Merck reported that the pivotal phase III Echo-301/Keynote-252 study testing Incyte’s epacadostat paired with Keytruda in individuals with unresectable or metastatic melanoma failed a review by the external data monitoring committee (DMC).